胰腺脂肪与未来血糖异常风险:系统综述与荟萃分析
本系统综述与荟萃分析纳入10项纵向观察性研究,评估基线胰腺脂肪与 incident 2型糖尿病(T2D)及血糖进展的纵向关联。主要二元荟萃分析(5项研究)显示高胰腺脂肪与 incident T2D 相关(合并效应估计2.56;95%CI 1.27-5.14;I2=93.3%),排除一项超声研究后关联仍存(1.45;95%CI 1.23-1.73;I2=10.2%)。连续分析(3项研究)及血糖进展(2项研究)亦支持关联,瘦人群证据有限但方向一致。
要点
- 高胰腺脂肪与 incident T2D 风险增加相关,排除异质性来源后关联稳定。
- 胰腺脂肪亦与血糖进展相关,但证据来自少量研究。
- 瘦人群证据有限,仅作叙述性合成,方向与总体一致。
核心结论
- 胰腺脂肪与未来不良血糖结局相关,支持其作为影像衍生标志物的潜在价值。
研究设计与样本
- 系统综述与荟萃分析,检索 PubMed、Embase、Web of Science 和 Cochrane Library 至2026年3月1日,纳入10项纵向观察性研究。
- 采用 Newcastle-Ottawa 量表评估方法学质量,两名评价者独立筛选和提取数据。
主要发现
- 主要二元荟萃分析(5项研究)中,较高胰腺脂肪与 incident T2D 相关(合并效应估计2.56;95%CI 1.27-5.14;I2=93.3%)。
- 排除1项有影响力的超声研究后,异质性降低而关联保留(合并效应估计1.45;95%CI 1.23-1.73;I2=10.2%)。
- 连续分析(3项研究)支持与 incident T2D 的关联(1.17;95%CI 1.04-1.32;I2=79.2%),但暴露尺度不可直接比较。
- 胰腺脂肪与血糖进展相关(2项研究;1.96;95%CI 1.10-3.48;I2=73.2%)。
- 瘦人群探索性证据限于2个分析背景,叙述性合成,方向与总体发现一致。
临床怎么用
- 胰腺脂肪可作为未来血糖异常的潜在影像标志物,但需结合暴露测量方法解读。
- 异质性部分由暴露确认方法差异解释,临床评估时应考虑影像模态的影响。
局限性
- 纳入研究数量少,部分分析仅2-3项研究,合并估计异质性较高。
- 连续分析中暴露尺度不可直接比较,瘦人群证据有限且为叙述性合成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pancreatic fat has emerged as a metabolically relevant ectopic fat depot, but its longitudinal association with future dysglycemic outcomes remains incompletely defined. OBJECTIVE: This study aims to evaluate the longitudinal association of pancreatic fat with incident type 2 diabetes (T2D) and glycemic progression, with exploratory narrative synthesis of evidence in lean populations. DATA SOURCES: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to March 1, 2026. STUDY SELECTION: Longitudinal observational studies assessing pancreatic fat at baseline and reporting subsequent incident T2D, glycemic progression, or both were included. DATA EXTRACTION: Two reviewers independently screened studies and extracted data. Methodological quality was assessed using the Newcastle-Ottawa Scale. DATA SYNTHESIS: Ten studies were included. In the primary binary meta-analysis (5 studies), higher pancreatic fat burden was associated with incident T2D (pooled effect estimate, 2.56; 95% CI, 1.27-5.14; I2 = 93.3%). Exclusion of 1 influential ultrasound-based study attenuated heterogeneity while preserving the association (pooled effect estimate, 1.45; 95% CI, 1.23-1.73; I2 = 10.2%). A separate continuous analysis (3 studies) also supported an association with incident T2D (1.17; 95% CI, 1.04-1.32; I2 = 79.2%), although exposure scales were not directly comparable. Pancreatic fat was also associated with glycemic progression (2 studies; 1.96; 95% CI, 1.10-3.48; I2 = 73.2%). Exploratory lean-population evidence was limited to 2 analytical contexts, synthesized narratively, and directionally consistent with the overall findings. CONCLUSION: Pancreatic fat was associated with adverse future glycemic outcomes across multiple analytical contexts. These findings support pancreatic fat as a potentially meaningful imaging-derived marker of future dysglycemia, while suggesting that heterogeneity is partly explained by differences in exposure ascertainment.
引用
- Yang J, Zhang X, Luo L, et al. Pancreatic fat and the risk of future dysglycemia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2026. PMID: 42258632. doi:10.1210/clinem/dgag222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。